var data={"title":"Cosyntropin (tetracosactide): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cosyntropin (tetracosactide): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5949?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cosyntropin-tetracosactide-drug-information\" class=\"drug drug_general\">see &quot;Cosyntropin (tetracosactide): Drug information&quot;</a> and <a href=\"topic.htm?path=cosyntropin-tetracosactide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cosyntropin (tetracosactide): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154800\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cortrosyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154801\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cortrosyn;</li>\n      <li>Synacthen Depot</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051966\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diagnostic Agent, Adrenocortical Insufficiency</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442271\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Dosing units may vary (ie, mcg, mcg/<b>kg</b>, or mcg/<b>m<sup>2</sup></b>); use extra precaution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adrenocortical insufficiency, diagnostic test (ACTH stimulation test):</b> Limited data available in preterm neonates; dosing regimens variable: <b>Note:</b> Both low-dose and standard-dose cosyntropin produce transient, supraphysiological plasma ACTH concentrations without significant adverse effects. Dosing should be determined by the clinician ordering and interpreting test results. Cosyntropin solution for injection formulation is not recommended for IM administration; use powder for injection formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Low-dose ACTH stimulation test</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed: Preterm neonates: Solution or powder for injection: IV: 1 mcg/<b>kg</b>/dose; reported range: 0.1 to 3.5 mcg/<b>kg</b>/dose (Cole 1999; Korte 1996; Watterberg 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dose: Limited data available: Solution or powder for injection: IV: 1 mcg (Bornstein 2016; Crawford 2017; Robert 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Standard-dose ACTH stimulation test</i>: Term neonates: IM (powder for injection), IV (solution or powder for injection):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed: Limited data available: 15 mcg/<b>kg</b>/dose (Bornstein 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dose: 125 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051960\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cosyntropin-tetracosactide-drug-information\" class=\"drug drug_general\">see &quot;Cosyntropin (tetracosactide): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing units may vary (ie, mcg, mcg/<b>kg,</b> or mcg/<b>m<sup>2</sup></b>); use extra precaution</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Adrenocortical insufficiency, diagnostic test (ACTH stimulation test): </b> <b>Note: </b>Both low-dose and standard-dose cosyntropin produce transient, supraphysiological plasma ACTH concentrations without significant adverse effects. Dosing should be determined by the clinician ordering and interpreting test results. Cosyntropin solution for injection formulation is not recommended for IM administration; use powder for injection formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Low-dose ACTH stimulation test: </i>Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &le;2 years: IV (solution or powder for injection): 1 mcg/<b>m<sup>2</sup></b>/dose; maximum dose: 1 mcg/dose (Lomenick 2007; Rose 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &gt;2 years and Adolescents: IV (solution or powder for injection): 1 mcg or 1 mcg/<b>m<sup>2</sup></b>/dose; maximum dose: 1 mcg/dose (Borenstein 2016; Cemeroglu 2011; Kazlauskaite 2008; Kazluaskaite 2010; Rose 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Standard-dose ACTH stimulation test: </i></p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Infants: IV (solution or powder for injection): 15 <b>mcg</b><b>/</b>kg; maximum dose: 125 mcg/dose (Borenstein 2016)</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Children &le;2 years: IV (solution or powder for injection): 125 mcg (Borenstein 2016)</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">Children &gt;2 years and Adolescents: IM (powder for injection), IV (solution or powder for injection): 250 mcg; doses in the range of 250 to 750 mcg have been used in clinical studies; however, maximal response is seen with 250 mcg dose. When greater cortisol stimulation is needed; an IV infusion may be used: 250 mcg administered over 6 hours (rate: 40 mcg/hour)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Congenital adrenal hyperplasia, evaluation:</b> Limited data available: Infants and Children: IM (powder for injection), IV (solution or powder for injection): 125 to 250 mcg (Speiser 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Adrenocortical insufficiency, diagnostic test: </b>Cosyntropin powder for injection (IM, IV) or cosyntropin solution for injection (IV only [manufacturer labeling does not recommend IM administration of solution for injection]): 250 mcg; <b>Note:</b> Doses in the range of 250 to 750 mcg have been used in clinical studies; however, maximal response is seen with 250 mcg dose. When greater cortisol stimulation is needed, an IV infusion may be used: 250 mcg administered at 40 mcg/hour over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154785\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cortrosyn: 0.25 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154772\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051970\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Powder for injection: Administer as 0.25 mg/mL (250 <b>mcg/</b>mL) concentration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection solution: Not recommended for IM administration per manufacturer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Administer over 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: Infuse over 4 to 8 hours (40 <b>mcg</b>/hour over 6 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154797\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for injection: Store at controlled room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV infusion: Stable for 12 hours at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Solution for injection: Store refrigerated between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light and freezing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV infusion: Stable for 12 hours at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suspension for injection: Synacthen Depot [Canadian product]: Store refrigerated between 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051969\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Diagnostic test to differentiate primary adrenal from secondary (pituitary) adrenocortical insufficiency [FDA approved in pediatric patients (age not specified) and adults]; has also been used in the diagnosis of congenital adrenal hyperplasia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154837\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cortrosyn may be confused with colchicine, corticorelin, corticotropin, Cotazym</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cosyntropin may be confused with corticorelin, corticotropin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154836\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events associated with other corticosteroids may be observed when Synacthen Depot (Canadian product) is used for therapeutic purposes. Refer to corticosteroid monographs for comprehensive lists.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cardiovascular: Bradycardia, hypertension, peripheral edema, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash, urticaria at injection site (with erythema)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Adrenal hemorrhage (Synacthen Depot)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154791\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to cosyntropin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Synacthen Depot [Canadian product]: Additional contraindications: Treatment of asthma or other allergic conditions (increased risk of anaphylactic reactions); use in premature babies and neonates &lt;1 month; acute psychosis; untreated bacterial, fungal, and viral infections; active or latent peptic ulcer; refractory heart failure; Cushing&rsquo;s syndrome; treatment of primary adrenocortical insufficiency; adrenogenital syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154776\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Corticotropin allergy: Cortrosyn: Use with caution in patients with a history of allergic reactions to corticotropin or preexisting allergic disease. Synacthen Depot [Canadian product] is contraindicated in patients with allergic conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Synacthen Depot [Canadian product]: Hypersensitivity reactions (including severe reactions) may occur particularly in patients with asthma or other allergies and often within 30 minutes of administration; monitor for hypersensitivity for ~1 hour after administration. Prolonged use may increase the risk of allergic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Synacthen Depot [Canadian product]: Use caution in patients with hypertension or thromboembolic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal disease: Synacthen Depot [Canadian product]: Use caution in patients with nonspecific ulcerative colitis, diverticulitis, or recent intestinal anastomosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic disease: Synacthen Depot [Canadian product]: Enhanced effects may be observed in patients with cirrhosis of the liver.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infections: Synacthen Depot [Canadian product]: Use caution in patients with acute or chronic infections (especially varicella or vaccinia) or exanthematous and fungal diseases. Use with caution in patients with latent tuberculosis; treatment may reactivate latent tuberculosis. Rule out amebiasis prior to initiating therapy; may activate latent amebiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Synacthen Depot [Canadian product]: Use caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Osteoporosis: Synacthen Depot [Canadian product]: Use caution in patients with osteoporosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal disease: Synacthen Depot [Canadian product]: Use caution in patients with renal insufficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Synacthen Depot [Canadian product]: Enhanced effects may be observed with hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage forms specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Synacthen Depot [Canadian product]: Contains benzyl alcohol; avoid use in infants and children &lt;3 years of age; contraindicated in neonates. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immunizations: Synacthen Depot [Canadian product]: Live vaccines should not be given concurrently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgery/trauma: Synacthen Depot [Canadian product]: Augmentation or resumption of therapy may be necessary in patients undergoing surgery or subjected to trauma either during or within 1 year of therapy discontinuation; adjunctive rapid acting corticosteroids may be necessary during periods of stress.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299097\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219534\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13183&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">ClonazePAM: Cosyntropin may enhance the hepatotoxic effect of ClonazePAM. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DiazePAM: Cosyntropin may enhance the hepatotoxic effect of DiazePAM. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitrazepam: Cosyntropin may enhance the hepatotoxic effect of Nitrazepam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Cosyntropin may enhance the hepatotoxic effect of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Cosyntropin may enhance the hepatotoxic effect of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Cosyntropin may enhance the hepatotoxic effect of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Cosyntropin may enhance the hepatotoxic effect of Valproate Products.  Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154782\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13447516\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with cosyntropin; adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts (Park-Wyllie 2000; Pradat 2003). Systemic corticosteroids may also influence fetal growth (decreased birth weight); however, information is conflicting (Lunghi 2010). When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010; Makol 2011; &Oslash;stensen 2009). Cosyntropin is the recommended test to diagnose primary adrenal insufficiency during pregnancy. Pregnancy may alter cortisol levels, and higher concentrations are used to interpret the results based on trimester (Bornstein 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051968\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma cortisol concentrations should be measured immediately before and exactly 30 minutes after the dose; dose should be given in the early morning; normal morning baseline cortisol &gt;5 mcg/dL (SI: &gt;138 nmol/L); normal response 30 minutes after cosyntropin injection: an increase in serum cortisol concentration of &ge;7 mcg/dL (SI: &ge;193 nmol/L) or peak response &gt;18 mcg/dL (SI: &gt;497 nmol/L). If increase in plasma cortisol levels at 30 minutes is equivocal, consider repeat cortisol sampling at 60 and/or 90 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154775\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates the adrenal cortex to secrete adrenal steroids (including hydrocortisone, cortisone), androgenic substances, and a small amount of aldosterone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154790\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IM, IV: Within 5 minutes increases in plasma cortisol concentrations are observed in healthy individuals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: IM, IV: 45-60 minutes peak plasma cortisol concentration </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Synacthen Depot [Canadian product]: IM: Plasma concentrations of 200-300 pg/mL maintained for 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Synacthen Depot [Canadian product]: IM: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Synacthen Depot [Canadian product]: V<sub>d</sub>: ~43% of body weight</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Synacthen Depot [Canadian product]: 7 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM, IV push: ~1 hour; plasma cortisol levels rise in healthy individuals within 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051975\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Each 0.25 mg of cosyntropin is equivalent to 25 units of corticotropin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323079\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cortrosyn Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (1): $127.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cosyntropin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (1): $105.81</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038590\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cortrosinta Depot (PT);</li>\n      <li>Cortrosyn (BE, HU);</li>\n      <li>Cortrosyn Depot (AE, BE, BF, BG, BH, BJ, CI, CY, CZ, EG, ET, FR, GH, GM, GN, HK, HN, HU, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, QA, SA, SC, SD, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Nuvacthen Depot (ES);</li>\n      <li>Synacthen (AR, AT, AU, BE, CH, CZ, DE, DK, GB, IE, IT, KR, LU, MT, NZ, PL, RO, RU, SE, SI);</li>\n      <li>Synacthen Deposito (CO, VE);</li>\n      <li>Synacthen Depot (AE, AT, AU, BF, BG, BH, BJ, CH, CI, CL, CY, CZ, DK, EG, ET, FI, GB, GH, GM, GN, GR, HN, HR, IL, IQ, IR, IT, JO, KE, KR, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, NZ, OM, PL, PT, QA, SA, SC, SD, SE, SL, SN, SY, TN, TR, TZ, UG, UY, YE, ZA, ZM, ZW);</li>\n      <li>Synacthene (FR, GR, IN, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdu TA, Elhadd TA, Neary R, et al, &quot;Comparison of the Low Dose Short Synacthen Test (1 Microg), the Conventional Dose Short Synacthen Test (250 Microg), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients With Pituitary Disease,&quot; <i>J Clin Endocrinol Metab</i>, 1999, 84(3):838-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/10084558/pubmed\" target=\"_blank\" id=\"10084558\">10084558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bornstein SR, Allolio B, ArltW, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/26760044/pubmed\" target=\"_blank\" id=\"26760044\">26760044</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cemeroglu AP, Kleis L, Postellon DC, et al, &quot;Comparison of Low-Dose and High-Dose Cosyntropin Stimulation Testing in Children,&quot; <i>Pediatr Int</i>, 2011, 53(2):175-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/20626639/pubmed\" target=\"_blank\" id=\"20626639\">20626639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cole CH, Shah B, Abbasi S, et al, &quot;Adrenal Function in Premature Infants During Inhaled Beclomethasone Therapy,&quot; <i>J Pediatr</i>, 1999, 135(1):65-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/10393606/pubmed\" target=\"_blank\" id=\"10393606\">10393606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosyntropin [prescribing information]. Rockford, IL: Mylan Institutional LLC; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crawford JH, Hull MS, Borasino S, et al. Adrenal insufficiency in neonates after cardiac surgery with cardiopulmonary bypass. <i>Paediatr Anaesth</i>. 2017;27(1):77-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/27779350/pubmed\" target=\"_blank\" id=\"27779350\">27779350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kazlauskaite R, Evans AT, Villabona CV, et al, &quot;Corticotropin Tests for Hypothalamic-Pituitary-Adrenal Insufficiency: A Metaanalysis,&quot; <i>J Clin Endocrinol Metab</i>, 2008, 93(11):4245-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/18697868/pubmed\" target=\"_blank\" id=\"18697868\">18697868</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kazlauskaite R, Maghnie M. Pitfalls in the diagnosis of central adrenal insufficiency in children. <i>Endocr Dev</i>. 2010;17:96-107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/19955760/pubmed\" target=\"_blank\" id=\"19955760\">19955760</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Korte C, Styne D, Merritt TA, et al, &quot;Adrenocortical Function in the Very Low Birth Weight Infant: Improved Testing Sensitivity and Association With Neonatal Outcome,&quot; <i>J Pediatr</i>, 1996, 128(2):257-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/8636825 /pubmed\" target=\"_blank\" id=\"8636825 \">8636825 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA and Reed BR, &quot;The Use of Dermatologic Drugs in Pregnancy and Lactation,&quot; <i>Dermatol Clin</i>, 2006, 24(2):167-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/16677965/pubmed\" target=\"_blank\" id=\"16677965\">16677965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lomenick JP, Smith WJ. Low-dose adrenocorticotropic hormone stimulation testing in term infants. <i>J Pediatr Endocrinol Metab</i>. 2007;20(7):773-779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/17849739/pubmed\" target=\"_blank\" id=\"17849739\">17849739</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lunghi L, Pavan B, Biondi C, et al, &quot;Use of Glucocorticoids in Pregnancy,&quot;<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/20977425/pubmed\" target=\"_blank\" id=\"20977425\">20977425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, and Amin S, &quot;Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management,&quot; <i>Drugs</i>, 2011, 71(15):1973-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marik PE, Pastores SM, Annane D, et al, &quot;Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine,&quot; <i>Crit Care Med</i>, 2008, 36(6):1937-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/18496365/pubmed\" target=\"_blank\" id=\"18496365\">18496365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M and Forger F, &quot;Management of RA Medications in Pregnant Patients,&quot; <i>Nat Rev Rheumatol</i>, 2009, 5(7):382-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/19506586/pubmed\" target=\"_blank\" id=\"19506586\">19506586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park-Wyllie L, Mazzotta P, Pastuszak A, et al, &quot;Birth defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies,&quot; <i>Teratology</i>, 2000, 62(6):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/11091360/pubmed\" target=\"_blank\" id=\"11091360\">11091360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/14745915/pubmed\" target=\"_blank\" id=\"14745915\">14745915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robert SM, Borasino S, Dabal RJ, Cleveland DC, Hock KM, Alten JA. Postoperative hydrocortisone infusion reduces the prevalence of low cardiac output syndrome after neonatal cardiopulmonary bypass.<i> Pediatr Crit Care Med</i>. 2015;16(7):629-636.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/25901540/pubmed\" target=\"_blank\" id=\"25901540\">25901540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rose SR, Lustig RH, Burstein S, Pitukcheewanont P, Broome DC, Burghen GA. Diagnosis of ACTH deficiency. Comparison of overnight metyrapone test to either low-dose or high-dose ACTH test. <i>Horm Res</i>. 1999;52(2):73-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/10681636/pubmed\" target=\"_blank\" id=\"10681636\">10681636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Speiser PW, Azziz R, Baskin LS, et al, &quot;Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline,&quot; <i>J Clin Endocrinol Metab</i>, 2010, 95(9):4133-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/20823466/pubmed\" target=\"_blank\" id=\"20823466\">20823466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Suominen PK, Keski-Nisula J, Ojala T, et al. Stress-dose corticosteroid versus placebo in neonatal cardiac operations: a randomized controlled trial. <i>Ann Thorac Surg</i>. 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/28434547/pubmed\" target=\"_blank\" id=\"28434547\">28434547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thaler LM and Blevins LS Jr, &quot;The Low Dose (1-Microg) Adrenocorticotropin Stimulation Test in the Evaluation of Patients With Suspected Central Adrenal Insufficiency,&quot; <i>J Clin Endocrinol Metab</i>, 1998, 83(8):2726-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/9709938/pubmed\" target=\"_blank\" id=\"9709938\">9709938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watterberg KL, Shaffer ML, Garland JS, et al, &quot;Effect of Dose on Response to Adrenocorticotropin in Extremely Low Birth Weight Infants,&quot; <i>J Clin Endocrinol Metab</i>, 2005, 90(12):6380-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/16159938/pubmed\" target=\"_blank\" id=\"16159938\">16159938</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13183 Version 100.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F154800\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F154801\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051966\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442271\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051960\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154785\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F154772\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051970\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F154797\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051969\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F154837\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154836\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154791\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154776\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299097\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219534\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154782\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13447516\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1051968\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154775\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F154790\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1051975\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323079\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038590\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13183|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cosyntropin-tetracosactide-drug-information\" class=\"drug drug_general\">Cosyntropin (tetracosactide): Drug information</a></li><li><a href=\"topic.htm?path=cosyntropin-tetracosactide-patient-drug-information\" class=\"drug drug_patient\">Cosyntropin (tetracosactide): Patient drug information</a></li></ul></div></div>","javascript":null}